In a report released today, Nadine Sarwat from Bernstein maintained a Hold rating on Canopy Growth (CGC – Research Report), with a price target of C$1.49. The company’s shares closed today at $1.15.
According to TipRanks, Sarwat is a 2-star analyst with an average return of 6.8% and a 33.33% success rate.
Canopy Growth has an analyst consensus of Moderate Sell, with a price target consensus of $0.85, representing a -26.09% downside. In a report released on September 14, TD Cowen also maintained a Hold rating on the stock with a C$1.80 price target.
See Insiders’ Hot Stocks on TipRanks >>
CGC market cap is currently $991.2M and has a P/E ratio of -0.73.
Based on the recent corporate insider activity of 50 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CGC in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Canopy Growth Corp. engages in the production and sale of medical cannabis. The company offers products including oils and concentrates, soft gel capsules and hemp. It focuses on the treatment of chronic pain, seizures, muscle spasms, nausea, and loss of appetite. The company was founded by Bruce Linton on August 5, 2009 and is headquartered in Smith Falls, Canada.
Read More on CGC:
